Sensible Biotechnologies
Unlocking the next generation of mRNA medicines
Synthetic Biology
Biotech
Manufacturing
Therapeutics
Biotechnology
About
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
Build your own investing agent
GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.
Join the GPAgent waitlistDetails
Status
Active
Stage
Early
Team Size
24
Regions
United Kingdom, Europe, Remote, Partly Remote